Electra Therapeutics closed an oversubscribed $183 million Series C to fund a global pivotal trial of ELA026, its monoclonal antibody targeting SIRP receptors, in secondary hemophagocytic lymphohistiocytosis (sHLH). The financing will also advance ELA822 and additional immunology and oncology indications. Electra has dosed first patients in the pivotal SURPASS study and plans to use historical-control registrational design elements. Management framed the round as positioning the company to carry programs through registrational milestones and broaden indications into blood cancers and inflammatory diseases.